SVSlavica Vuckovic

Slavica Vuckovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Slavica Vuckovic has a total of 148 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S1 from ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome

    by Melody Cheong, Kate H. Gartlan, Jason S. Lee, Siok-Keen Tey, Ping Zhang, Rachel D. Kuns, Christopher E. Andoniou, Jose Paulo Martins, Karshing Chang, Vivien R. Sutton, et al.

  • Open Access

    Supplementary Table S1 from ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome

    by Melody Cheong, Kate H. Gartlan, Jason S. Lee, Siok-Keen Tey, Ping Zhang, Rachel D. Kuns, Christopher E. Andoniou, Jose Paulo Martins, Karshing Chang, Vivien R. Sutton, et al.

  • Open Access

    Supplementary Figure S1 from ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome

    by Melody Cheong, Kate H. Gartlan, Jason S. Lee, Siok-Keen Tey, Ping Zhang, Rachel D. Kuns, Christopher E. Andoniou, Jose Paulo Martins, Karshing Chang, Vivien R. Sutton, et al.

    Supplementary Figure S1: GVHD survival of lethally-irradiated (day 0, 1000cGy split dose) B6.WT, B6.ASC-/- or B6.NLRP3-/- recipients transplanted with BALB/c BM (5x106) and T cells (5x106). The non-GVHD control group received TCD BM cells (5x106) only. Results combined from 2 independent experiments (n = 20 per T cell-replete group, n = 8 for TCD BM group). ****P < 0.0001; B6.NLRP3-/- vs. B6.WT. Results are presented as means {plus minus} SEM.

  • Open Access

    Supplementary Table S1 from ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome

    by Melody Cheong, Kate H. Gartlan, Jason S. Lee, Siok-Keen Tey, Ping Zhang, Rachel D. Kuns, Christopher E. Andoniou, Jose Paulo Martins, Karshing Chang, Vivien R. Sutton, et al.

    Supplementary Table S1 (related to Fig. 4A): (A) Ingenuity Pathway Analysis derived from the uncorrected dataset displaying top canonical signaling pathways involving differentially regulated genes in recipients as described in Fig.4A. (B) 10 selected immunologically relevant genes identified as differentially regulated in mice transplanted with B6.WT or B6.ASC-/- grafts.

  • Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity

    by Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Nicole S. Nemychenkov, Christine R. Schmidt, Shruti S. Bhise, Samuel R. W. Legg, Gabriela Campoy, Luke D. Samson, Rachel D. Kuns, et al.

    Some hematological malignancies such as multiple myeloma are inherently resistant to immune-mediated antitumor responses, the cause of which remains unknown. Allogeneic bone marrow transplantation (alloBMT) is the only curative immunotherapy for hematological malignancies due to profound graft-versus-tumor (GVT) effects, but relapse remains the major cause of death. We developed murine models of alloBMT where the hematological malignancy is either sensitive [acute myeloid leukemia (AML)] or resistant (myeloma) to GVT effects. We found that CD8 + T cell exhaustion in bone marrow was primarily alloantigen-driven, with expression of inhibitory ligands present on myeloma but not AML. Because of this tumor-independent exhaustion signature, immune checkpoint inhibition (ICI) in myeloma exacerbated graft-versus-host disease (GVHD) without promoting GVT effects. Administration of post-transplant cyclophosphamide (PT-Cy) depleted donor T cells with an exhausted phenotype and spared T cells displaying a stem-like memory phenotype with chromatin accessibility present in cytokine signaling genes, including the interleukin-18 (IL-18) receptor. Whereas ICI with anti–PD-1 or anti–TIM-3 remained ineffective after PT-Cy, administration of a decoy-resistant IL-18 (DR-18) strongly enhanced GVT effects in both myeloma and leukemia models, without exacerbation of GVHD. We thus defined mechanisms of resistance to T cell–mediated antitumor effects after alloBMT and described an immunotherapy approach targeting stem-like memory T cells to enhance antitumor immunity.


  • Open Access

    Inverse relationship between oligoclonal expanded CD69− TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients

    by Slavica Vuckovic, Christian E. Bryant, Ka Hei Aleks Lau, Shihong Yang, James Favaloro, Helen M. McGuire, Georgina Clark, Barbara Fazekas de St. Groth, Felix Marsh-Wakefield, Najah Nassif, et al.

    CD8+CD57+ terminal effector T (TTE) cells are a component of marrow-infiltrating lymphocytes and may contribute to the altered immune responses in multiple myeloma (MM) patients. We analyzed TTE cells in the bone marrow (BM) and peripheral blood (PB) of age-matched controls and patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), and newly diagnosed (ND) MM using flow cytometry, mass cytometry, and FlowSOM clustering. TTE cells are heterogeneous in all subjects, with BM containing both CD69− and CD69+ subsets, while only CD69− cells are found in PB. Within the BM-TTE compartment, CD69− and CD69+ cells are found in comparable proportions in controls, while CD69− cells are dominant in MGUS and SMM and predominantly either CD69− or CD69+ cells in NDMM. A positive relationship between CD69+TTE and CD69−TTE cells is observed in the BM of controls, lost in MGUS, and converted to an inverse relationship in NDMM. CD69−TTE cells include multiple oligoclonal expansions of T-cell receptor/Vβ families shared between BM and PB of NDMM. Oligoclonal expanded CD69−TTE cells from the PB include myeloma-reactive cells capable of killing autologous CD38hi plasma cells in vitro, involving degranulation and high expression of perforin and granzyme. In contrast to CD69−TTE cells, oligoclonal expansions are not evident within CD69+TTE cells, which possess low perforin and granzyme expression and high inhibitory checkpoint expression and resemble T resident memory cells. Both CD69−TTE and CD69+TTE cells from the BM of NDMM produce large amounts of the inflammatory cytokines interferon-γ and tumor necrosis factor α. The balance between CD69− and CD69+ cells within the BM-TTE compartment may regulate immune responses in NDMM and contribute to the clinical heterogeneity of the disease.


  • Open Access

    Mass Cytometry Discovers Two Discrete Subsets of CD39−Treg Which Discriminate MGUS From Multiple Myeloma

    by Felix Marsh-Wakefield, Annabel Kruzins, Helen M. McGuire, Shihong Yang, Christian Bryant, Barbara Fazekas de St. Groth, Najah Nassif, Scott N. Byrne, John Gibson, Christina Brown, et al.

    Multiple Myeloma (MM) is preceded by the clinically stable condition monoclonal gammopathy of undetermined significance (MGUS). Critical immune events that discriminate MGUS from newly diagnosed MM (ND)MM patients remain unknown, but may involve changes in the regulatory T cell (Treg) compartment that favor myeloma growth. To address this possibility, we used mass cytometry and the unsupervised clustering algorithm Flow self-organizing map (FlowSOM) to interrogate the distribution of multiple subsets within CD25+CD127low/negTreg in matched bone marrow (BM) and peripheral blood (PB) of MGUS and NDMM patients. Both mass cytometry and flow cytometry confirmed a trend toward prevalence of CD39−Treg within the Treg compartment in BM and PB of NDMM patients compared to CD39−Treg in MGUS patients. FlowSOM clustering displayed a phenotypic organization of Treg into 25 metaclusters that confirmed Treg heterogeneity. It identified two subsets which emerged within CD39−Treg of NDMM patients that were negligible or absent in CD39−Treg of MGUS patients. One subset was found in both BM and PB which phenotypically resembled activated Treg based on CD45RO, CD49d, and CD62L expression; another subset resembled BM-resident Treg based on its tissue-resident CD69+CD62L−CD49d− phenotype and restricted location within the BM. Both subsets co-expressed PD-1 and TIGIT, but PD-1 was expressed at higher levels on BM-resident Treg than on activated Treg. Within BM, both subsets had limited Perforin and Granzyme B production, whilst activated Treg in PB acquired high Perforin and Granzyme B production. In conclusion, the use of mass cytometry and FlowSOM clustering discovered two discrete subsets of CD39−Treg which are discordant in MGUS and NDMM patients and may be permissive of myeloma growth which warrants further study. Understanding the regulatory properties of these subsets may also advance MGUS and MM diagnosis, prognosis, and therapeutic implications for MM patients.


  • Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model

    by Camille Guillerey, Kyohei Nakamura, Andrea C. Pichler, Deborah Barkauskas, Sophie Krumeich, Kimberley Stannard, Kim Miles, Heidi Harjunpää, Yuan Yu, Mika Casey, et al.

    Immunotherapy holds promise for patients with multiple myeloma (MM), but little is known about how MM-induced immunosuppression influences response to therapy. Here, we investigated the impact of disease progression on immunotherapy efficacy in the Vk*MYC mouse model. Treatment with agonistic anti-CD137 (4-1BB) mAbs efficiently protected mice when administered early but failed to contain MM growth when delayed more than 3 weeks after Vk*MYC tumor cell challenge. The quality of the CD8 + T cell response to CD137 stimulation was not altered by the presence of MM, but CD8 + T cell numbers were profoundly reduced at the time of treatment. Our data suggest that an insufficient ratio of CD8 + T cells to MM cells (CD8/MM ratio) accounts for the loss of anti-CD137 mAb efficacy. We established serum M-protein levels prior to therapy as a predictive factor of response. Moreover, we developed an in silico model to capture the dynamic interactions between CD8 + T cells and MM cells. Finally, we explored two methods to improve the CD8/MM ratio: anti-CD137 mAb immunotherapy combined with Treg depletion or administered after chemotherapy treatment with cyclophosphamide or melphalan efficiently reduced MM burden and prolonged survival. Together, our data indicate that consolidation treatment with anti-CD137 mAbs might prevent MM relapse.


  • Bone marrow transplantation generates T cell–dependent control of myeloma in mice

    by Slavica Vuckovic, Simone A. Minnie, David Smith, Kate H. Gartlan, Thomas S. Watkins, Kate A. Markey, Pamela Mukhopadhyay, Camille Guillerey, Rachel D. Kuns, Kelly R. Locke, et al.

    Transplantation with autologous hematopoietic progenitors remains an important consolidation treatment for multiple myeloma (MM) patients and is thought to prolong disease plateau-phase by providing intensive cytoreduction. However, transplantation induces inflammation in the context of profound lymphodepletion that may cause hitherto unexpected immunological effects. We developed preclinical models of bone marrow transplantation (BMT) for MM using Vk*MYC myeloma-bearing recipients and donors that were myeloma-naïve or were myeloma-experienced to simulate autologous transplantation. Surprisingly, we demonstrate broad induction of T cell-dependent myeloma control, most efficiently from memory T cells within myeloma-experienced grafts, but also through priming of naïve T cells after BMT. CD8+ T cells from mice with controlled myeloma had a distinct TCR repertoire and higher clonotype overlap relative to myeloma-free BMT recipients. Furthermore, T cell-dependent myeloma control could be adoptively transferred to secondary recipients, and was myeloma clone-specific. Interestingly, donor-derived IL-17A acted directly on myeloma cells expressing the IL-17-receptor to induce a transcriptional landscape that promoted tumor growth and immune escape. Conversely, donor IFNγ secretion and signaling was critical to protective immunity, and was profoundly augmented by CD137 agonists. These data provide new insights into the mechanisms of action of transplantation in myeloma and suggests rational approaches to improving clinical outcome.


  • Top Cited Papers

    Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade

    by Simone A. Minnie, Rachel D. Kuns, Kate H. Gartlan, Ping Zhang, Andrew N. Wilkinson, Luke Samson, Camille Guillerey, Christian Engwerda, Kelli P. A. MacDonald, Mark J. Smyth, et al.

    Autologous stem cell transplantation (auto-SCT) remains a standard of care for multiple myeloma patients and prolongs progression-free survival. A small cohort of patients achieve long-term control of disease, however the majority of patients ultimately relapse, and the mechanisms permitting disease progression remain unclear. In this study, we used a preclinical model of autologous SCT for myeloma where the disease either progressed (MM-relapsed) or was controlled. In the bone marrow (BM), inhibitory receptor expression on CD8+ T-cells correlated strongly with myeloma progression after transplant. In conjunction, the co-stimulatory/adhesion receptor CD226 (DNAM-1) was markedly downregulated. Interestingly, DNAM-1- CD8+ T-cells in MM-relapsed mice had an exhausted phenotype, characterized by upregulation of multiple inhibitory receptors, including immunoglobulin and ITIM domains (TIGIT), programmed death 1 (PD-1) with decreased T-bet and increased Eomesodermin expression. Immune checkpoint blockade using monoclonal antibodies against PD-1 or TIGIT significantly prolonged myeloma control after SCT. Furthermore, CD8+ T-cells from MM-relapsed mice exhibited high interleukin-10 (IL-10) secretion that was associated with increased TIGIT and PD-1 expression. However, while donor-derived IL-10 inhibited myeloma control post-SCT, this was independent of IL-10 secretion by, or signaling to T-cells. Instead, the donor myeloid compartment, including CSF-1R-dependent macrophages and an IL-10-secreting dendritic cell population in the BM, promoted myeloma progression. Our findings highlight PD-1 or TIGIT blockade in conjunction with SCT as a potent combination therapy in the treatment of myeloma. Key points Myeloma promotes CD8+ T-cell exhaustion and IL-10 secretion from dendritic cells. PD-1 and TIGIT-targeted checkpoint inhibition is effective after SCT.